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Abstract
Background: Migration and proliferation of vascular endothelial cells are essential for repair of injured endothelium and
angiogenesis. Cyclins, cyclin-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors play an important role in
vascular tissue injury and wound healing. Previous studies suggest a link between the cell cycle and cell migration: cells
present in the G1 phase have the highest potential to migrate. The molecular mechanism linking these two processes is not
understood.
Methodology/Principal Findings: In this study, we explored the function of STK35L1, a novel Ser/Thr kinase, localized in the
nucleus and nucleolus of endothelial cells. Molecular biological analysis identified a bipartite nuclear localization signal, and
nucleolar localization sequences in the N-terminal part of STK35L1. Nuclear actin was identified as a novel binding partner of
STK35L1. A class III PDZ binding domains motif was identified in STK35L1 that mediated its interaction with actin. Depletion
of STK35L1 by siRNA lead to an accelerated G1 to S phase transition after serum-stimulation of endothelial cells indicating an
inhibitory role of the kinase in G1 to S phase progression. Cell cycle specific genes array analysis revealed that one gene was
prominently downregulated (8.8 fold) in STK35L1 silenced cells: CDKN2A alpha transcript, which codes for p16
INK4a leading
to G1 arrest by inhibition of CDK4/6. Moreover in endothelial cells seeded on Matrigel, STK35L1 expression was rapidly
upregulated, and silencing of STK35L1 drastically inhibited endothelial sprouting that is required for angiogenesis.
Furthermore, STK35L1 depletion profoundly impaired endothelial cell migration in two wound healing assays.
Conclusion/Significance: The results indicate that by regulating CDKN2A and inhibiting G1- to S-phase transition STK35L1
may act as a central kinase linking the cell cycle and migration of endothelial cells. The interaction of STK35L1 with nuclear
actin might be critical in the regulation of these fundamental endothelial functions.
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Introduction
Endothelial dysfunction underlies atherosclerosis and coronary
heart disease [1,2]. Migration and proliferation of vascular
endothelial cells are important not only for repair of injured
endothelium, but also for angiogenesis [3]. Cells in the
endothelial monolayer are in a quiescent state residing in the
Go phase of the cell cycle. Injury of the endothelium leads to the
local release of peptide growth factors (such as VEGF, TGF) and
bioactive lipids (i.e. S1P) that stimulate endothelial cell migration
and proliferation crucial for endothelial healing [4,5]. Angiogen-
esis induced by hypoxic tissue conditions or by angiogenic stimuli,
is a complex biological process involving the directional
migration, proliferation, intercellular alignment and adhesion of
endothelial cells [3]. Healing of the endothelium and angiogenesis
require the activation of a genetic program which regulates
endothelial cell proliferation and migration in a coordinated
manner.
Cyclins, the cyclin-dependent kinases (CDKs), and the cyclin-
dependent kinase inhibitors (CKIs) play an important role in
vascular tissue injury, inflammation and wound repair [6,7]. On
stimulation by growth factors or after mechanical trauma,
endothelial cells exit the quiescent state and progress through G1
and S phase of the cell cycle. G1 phase progression is regulated by
the assembly and phosphorylation of CDK complexes. Two
classes of endogenous inhibitors of the CKI are dominant in
cardiovascular biology: the CIP/KIP family, which includes
p21
Cip1, p27
Kip1, p57
Kip2, and the INK4 family, which includes
p15
Ink4b, p16
Ink4a, p18
Ink4c, and p19
Ink4d. p16
INK4a binds to
cyclin/CDK complexes and causes cell cycle arrest in the G1
phase by inhibiting CDK4/6 mediated phosphorylation of Rb [8].
p16
INK4a and p15
INK4b are encoded by the alpha-transcript of
CDKN2A and the CDKN2B gene, respectively. Recent genome-
wide association scanning studies identified DNA sequence
variants at chromosome 9p21 that increase the risk of coronary
heart disease, myocardial infarction and, independently, type 2
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16249diabetes [9,10]. Interestingly, the genomic region of interest was
found to be adjacent to the genes CDKN2A and CDKN2B. The
mechanism by which these genes might influence coronary heart
disease and type 2 diabetes is unknown.
Previous studies of vascular cells show that there is a link
between cell cycle progression and migration [11,12,13]. The
maximal potential of a cell to migrate lies in the mid-late G1
phase, whereas cells in the late S or G2/M phase have a lower or
no ability to move [14,15]. p27
Kip1 has been shown to regulate
G1-S phase cell cycle progression and cell migration of
endothelial and smooth muscle cells [13,16]. Endothelial cell
migration requires dynamic changes of the actin cytoskeleton
which is regulated by small GTPases and various protein kinases
[17]. The molecular mechanisms linking in endothelial cells cell
cycle progression and migration are not known.
STK35L1 is a member of the class of serine/threonine protein
kinases; it is mainly localized in the nucleolus and nucleus [18].
Recently we identified the full length coding sequence of the
STK35L1 gene which codes for a protein of 534 amino acids [18].
The biological function of STK35L1 is not known. STK35L1 gene
expression was found to be upregulated in colorectal cancer [19],
and was altered in a rodent model of Parkinson disease [20]. A
kinome-wide RNAi screen revealed that STK35L1 silencing was
among top five hits leading to reduce infection of hepatocytes by
Plasmodium berghei sporozoites [21]. These studies suggest that
STK35L1 may play a role in various human diseases.
In the present study we set out to explore the function of
STK35L1 in endothelial cells. We show that STK35L1 regulates
the expression of CDKN2A alpha-transcript and inhibits the G1-
to S-phase transition of the cell cycle, and that STK35L1 is
essential for endothelial cell migration and angiogenesis.
STK35L1 might be part of a program underlying the integrated
regulation of the cell cycle and cell migration.
Results
The N-terminal region of STK35L1 has functional nuclear
and nucleolar localization signals
We have previously shown that STK35L1 is mainly localized in
the nucleolus and the nucleus [18]. To predict a functional nuclear
localization signal (NLS) in STK35L1, the basic amino acid-rich
motifs of STK35L1 were analyzed by manual comparison with
known NLSs of different proteins. A potential bipartite NLS was
identified within the N-terminal motif (amino acids (aa) 142–153) of
theprotein.UnliketheclassicalbipartiteNLSconsistingofadefined
spacer of 8–10 non-basic amino acids, the identified potential NLS
of STK35L1 has a 6-amino acids short spacer sequence similar to
LIMK2 (Figure 1A) [22]. The identified NLS is highly conserved
among mammals (Figure S1). Conservation of the identified
bipartite NLS sequence underlies its functional importance.
To analyze whether the predicted NLS is functional, we
prepared various EGFP-tagged deletion constructs of STK35L1
(Figure 1B). As compared with EGFP-STK35L1 that predomi-
nantly localized in the nucleus and nucleolus, the constructs
deleted of the N-terminal 169 aa (EGFP-STK35L1D1-169)
containing mainly the kinase domain, was distributed throughout
the cytoplasm and the nucleus (Figure 1C). The construct
containing the predicted NLS (EGFP-STK35L1-134-201) mainly
accumulated in the nucleus (Figure 1C). These data suggest that
the motif aa 142–153 is the functional bipartite NLS of STK35L1.
Nucleolar localization signal (NoLS) are sequences rich in
arginine and lysine. So far, no specific consensus sequences for
nucleolar localization have been determined. We observed that
several stretches of arginine and lysine amino acids are present in
the N-terminal part of STK35L1 that are also highly conserved
among mammals (Figure S1). These analyses suggest a putative
NoLS in the N-terminal region of STK35L1. We found that the
mutant EGFP-STK35L1D1-133 (aa 1–133 were deleted) was
excluded from the nucleolus but mainly localized in the nucleus
(Figure 1C). This mutant corresponds to the protein previously
described as STK35 [18]. Our data indicate that the N-terminal
aa 1–133 contains a functional nucleolar localization signal (NoLS)
in STK35L1 that is absent in STK35.
EGFP-STK35 interacts with nuclear actin
STK35L1 is localized in the nucleus and nucleolus whereas
STK35 is mainly localized in the nucleus [18]. To identify proteins
which interact with STK35L1 in the nucleus, we immunoprecip-
itated EGFP-FLAG-STK35 protein from nuclear extracts of
EGFP-FLAG-STK35-transfected HEK293 cells using an anti-
FLAG antibody. We found four co-immunoprecipitated proteins
which were identified by MALDI-MS analysis as EGFP-STK35 (2
bands), HSP70B1 and actin (Figure 2A, left panel). The co-
immunoprecipitation of actin with EGFP-FLAG-STK35 was
confirmed by western blotting using a specific anti-b-actin
antibody (Figure 2A, middle panel). The purity of the nuclear
preparation was checked by probing it with an anti-b-tubulin
antibody that detected tubulin in the cytoplasmic fraction only
indicating that the nuclear preparation was free from cytoplasmic
proteins (Figure 2A, right panel). b-actin was present in both the
nucleus and the cytoplasm. These data suggest that STK35L1
interacts with nuclear actin.
To investigate further a possible colocalization of STK35 with
nuclear b-actin, endothelial cells were studied by fluorescence
microscopy. In transfected endothelial cells, EGFP-STK35 (green)
was concentrated in dot-like structures within the nucleus
(Figure 2B left panel). In some of these nuclear structures, b-actin
(red) was colocalized with EGFP-STK35 (Figure 2B right panel).
Together these data suggest that STK35L1 interacts with actin in
the nucleus of endothelial cells.
A potential class III PDZ domain binding motif of
STK35L1 is responsible for its association with actin
To gain insight into protein-protein interaction domains of
STK35L1, we used the Eukaryotic Linear Motif server (ELM) for
investigating candidate short non-globular functional motifs within
the STK35L1 protein [23]. Several protein-binding motifs were
predicted that were mainly located in the first 200 amino acids of
STK35L1 (Table S1). Among the motifs, an internal class III PDZ
domain-binding motif (PDZ-BM) was predicted in the N-terminal
part of STK35L1 (aa 173–176; Figure 3A). PDZ domains are
found in many proteins, also in proteins, that are involved in the
regulation of the actin cytoskeleton [24,25]. To test whether the
PDZ-BM is responsible for actin association, we performed GST
pull down assay of nuclear lysates from HeLa and endothelial cells
using a recombinant GST-tagged protein containing the potential
PDZ-BM (GST-PDM). GST-PDM consists of GST coupled to 30
amino acids (aa position 170 to 204) of STK35L1 containing the
potential PDZ-BM. Indeed, we found that the purified protein
GST-PDM but not GST bound with nuclear actin (Figure 3B).
To furtherstudy,whetherthe PDZ-BM associates ofSTK35L1 with
actin in vivo, we studied the localization of EGFP-PDM (STK35L1-
170–204) in transfected endothelial cells. We found that EGFP-PDM,
present both in the cytoplasm and the nucleus due to the small size of
the protein and the lack of NLS and NoLS sequences, strongly
associated with actin stress fibers (Figure 3C, left panel). EGFP-PDM
was not only localized on stress fibers, it was also enriched in
membrane ruffles of migrating endothelial cells (Movie S1).
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association of STK35L1 with actin, we investigated the subcellular
distribution of different EGFP-tagged deletion mutants of EGFP-
STK35L1 in transfected endothelial cells. The deletion mutant
containing the PDZ-BM but lacking the NoLS and NLS (EGFP-
STK35L1D1-169) resulted in a more cytoplasmic distribution of
the fusion protein than EGFP-STK35L1 with a partial localization
on fiber-like structures of the cytoskeleton (Figure 3C, middle
panel). The deletion mutant that lacked the PDZ-BM in addition
to NoLS and NLS (EGFP-STK35L1D1-196) was diffusely
distributed throughout the cytoplasm and the nucleus (Figure 3C,
right panel). In none of the transfected cells a fiber-like structure
could be observed.
Together, we suggest that a class III PDZ domain binding motif
is responsible for the association of STK35L1 with actin.
SiRNA-mediated depletion of STK35L1 accelerates G1-S
phase progression of the endothelial cell cycle
To analyze the role of nucleolar STK35L1 in the cell cycle, we
used siRNA to silence the STK35L1 gene. We designed siRNA
directed against three different regions of the STK35L1 gene [18]
which together down-regulated STK35L1 by 80–90% at the level
of transcription (Figure 4A) and at the level of protein [18].
siRNA- or nonspecific siRNA-transfected cells were synchronized
in G0/G1 phase by serum depletion, and thereafter the cells were
released into cell cycle progression by adding 10% serum. In
synchronized cells, over 80% of control and STK35L1-silenced
cells accumulated in the G0/G1 phase. Six hours after release, the
number of control cells in the G1/G0 phase was decreased by 6%,
and 12% of control cells were present in the S phase (Figure 4B).
In STK35L1-silenced cells, the G1-S phase transition was
accelerated: the number of cells in the G1/G0 phase was decreased
by 18% (p,0.05), and the number of cells in the S phase was
increased almost two fold (23%; Figure 4B, 6 hr). Twelve hours
after release, 68% (64%) of control cells were in the G1/G0 phase
and 19% (66%) had entered S phase. After STK35L1 silencing
only 55% cells remained in G1/G0 phase, and 29% of cells had
entered the S phase (Figure 4B).
These data indicate that knockdown of the STK35L1 gene
leads to an accelerated G1 to S phase transition. STK35L1 might
therefore function as a negative regulator of the cell cycle
progression from G1 to S phase.
Figure 1. Nuclear and nucleolar localization signals in STK35L1. A) Prediction of nuclear localization signals in STK35L1. NLS was aligned with
the known monopartite NLS of ESXR1 and bipartite NLSs of Plk1[22], LIMK2 [22] and HDGF [49]. Basic amino acids are shown in red colors. B)
Schematic representation of different EGFP-STK35L1 deletion mutants. The upper axis with coordinates represents the position of amino acids. The
predicted bipartite NLS (aa 142–153) is shown as red box. C) Subcellular distribution of different EGFP-STK35L1 deletion mutants. EGFP-STK35L1 was
mainly localized in the nucleus and nucleolus (Top left panel; white arrow). The nucleolus appears as a dark spot excluded by the DNA staining with
Hoechst-dye (lower left panel, white arrow head). The expression of the various EGFP-STK35L1 deletion mutants in endothelial cells is shown (see text
for details).
doi:10.1371/journal.pone.0016249.g001
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To determine the influence of STK35L1 on genes involved in
cell cycle regulation, a real-time RT-PCR-based commercial gene
array was used. This gene array measures the expression of 84
genes that include positive and negative regulation of the cell cycle,
phase transitions, checkpoints, and DNA replication (Table S2).
Endothelial cells were transfected with STK35L1 siRNA or
control siRNA, followed by cell synchronization in G0/G1 phase
and then released by serum stimulation.
Since we found in STK35L1-silenced cells an acceleration of
the G1/S- phase transition, we expected that by STK35L1-
silencing the expression of those genes might be altered, which
function during G1/S phase transition. Indeed, the most
prominently downregulated gene (8.8 fold) was p16
INK4a
(Table 1). This protein is encoded by the alpha-transcript of
CDKN2A gene [8], inhibits the cell cycle and is responsible for
arresting cells in the G1-phase. We were unable to detect
p16
INK4a, which is expressed probably at a very low level in
HUVEC by immunoblotting using commercial antibodies in
HUVEC. Also another study was unable to detect p16
INK4a in
HUVEC under normal growth condition [26].
Two other genes were significantly down-regulated in
STK35L1-silenced cells: GADD45A, a protein involved in DNA
repair as well as in G1 cell cycle arrest [27], and DDX11, which
encodes a nucleolar helicase (Table 1). No gene was significantly
upregulated in STK35L1 silenced cells. These data suggest that
STK35L1 might function as a negative regulator for the cell cycle
progression by affecting the expression levels of genes, which
inhibit the G1- to S-phase transition, such as p16
INK4a and
GADD45A.
STK35L1 is upregulated during angiogenesis
Endothelial cells cultivated on a basal membrane-like matrix
such as Matrigel, undergo a rapid morphogenesis: they migrate on
the matrix, form cell–cell contacts and a network of cords, but they
do not proliferate. In contrast, cells cultivated on collagen-coated
surfaces undergo mainly proliferation [28]. We reasoned that
STK35L1 expression might inhibit endothelial cell proliferation
on basal membrane-like matrix, and perhaps increase the
Figure 2. EGFP-STK35 intracts with nuclear actin. A) Nuclear actin coimmunoprecipitates with EGFP-FLAG-STK35. HEK293T cells were
transfected with EGFP-FLAG-STK35 and EGFP-FLAG. The nuclei were isolated and EGFP-FLAG-tagged proteins were immunoprecipitated with anti-
FLAG antibody. Bound proteins were resolved by SDS-PAGE and stained with Coomassie blue. The specific bands were cut, in-gel digested by trypsin
and identified by MALDI-TOF and peptide mass fingerprinting. The protein band around 45 kDa (under ‘‘*’’) was as b-actin (left panel). The other
bands were identified as HSP70B1 and EGFP-FLAG-STK35. The same immunoprecipitated samples were blotted with monoclonal anti-actin antibody
and the band of 45 kDa was confirmed as b-actin (middle panel). To check the purity of the nuclear preparation, 10 ml of 100 ml nuclear fraction and
10 ml of 4 ml cytoplasmic fraction were subjected to SDS-PAGE and blotted with an anti-actin and an anti-tubulin antibody. The apparent 50:50 ratio
of nuclear to cytoplasmic actin is due to the high amount of actin in the diluted cytoplasmic fraction. Tubulin (55 kDa) could be detected in the
cytoplasmic but not in the nuclear fraction, demonstrating the nuclear fraction was free from cytoplasmic proteins (right panel). B) EGFP-STK35 and b-
actin colocalized partially in the nucleus. Endothelial cells transfected with EGFP-STK35 (left panel, green) and stained for b-actin (middle panel, red)
with anti-actin monoclonal antibody (clone C4) 8 h after transfection. The overlay (right panel) shows colocalization of EGFP-STK35 and b-actin.
Arrows indicate some sites of colocalization.
doi:10.1371/journal.pone.0016249.g002
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Therefore, we compared first the effect of the two different
matrices (Matrigel and collagen) on STK35L1 expression of
endothelial cells. Indeed we found that the expression of
STK35L1 transcripts was increased threefold within 4 hours
only in the cells growing on basal membrane-like matrix
(Figure 5A).
Knockdown of STK35L1 inhibits the formation of
endothelial sprouting
Next, we analyzed whether silencing of STK35L1 affects the
morphogenesis of endothelial cells on Matrigel. Endothelial cells
transfected with control siRNA formed six hours after plating a
network of cord-like structures on basal membrane-like matrix
(Matrigel) similar to non-transfected cells (Figure 5B). In contrast,
in STK35L1-silenced cells endothelial sprouting was drastically
inhibited (by 70%; Figure 5B, 5C). The silenced cells also showed
considerably fewer nodes with branching outlets (Figure 5B lower
panel). These data indicate that STK35L1 regulates the
morphogenetic process required for angiogenesis.
STK35L1 silencing inhibits endothelial cell migration
In order to find out, which step of morphogenesis is affected in
STK35L1-silenced cells, we analyzed the migration of STK35L1-
silenced endothelial cells by using two different wound-healing
assays. In the assay using the IBIDI Culture-Insert where no cell
damage occurs, the migration of STK35L1-silenced cells was
drastically inhibited: the cells were not able to move in the
direction of the wound (Movie S2, Figure 6A). In STK35L1-
silenced cells, we could not observe the stable lamellipodia
formation in the direction of migration (like in control), but we
found transient lamellipodia formation in all the directions (Movie
S2). Also after mechanical injury of confluent endothelium, where
cell damage occurs, the migration of STK35L1-silenced cells was
inhibited (Figure 6B, 4C). These results show that STK35L1 is
crucial for endothelial cell migration.
Discussion
The present study demonstrates that the localization of the
novel kinase STK35L1 in the nucleus and nucleolus is regulated
Figure 3. Identification of Putative class III PDZ-binding domains motif in STK35L1 that mediates its interaction with actin. A) Class III
PDZ binding domains motif (PDZ-BM) was predicted by ELM software and its position within the STK35L1 sequence is indicated as green box; kinase
domain: yellow box, NLS: red box. B) GST pull down assay of nuclear lysates from HeLa cells was preformed using recombinant GST or GST-PDM
protein (GST coupled to 30 amino acids (aa position 170 to 204) of STK35L1 containing the potential PDZ-BM). Bound proteins were resolved by SDS-
PAGE and immunoblotted using a monoclonal anti-b-actin antibody C) Subcellular distribution of different EGFP-STK35L1 deletion mutants in
transfected endothelial cells. EGFP-PDM (aa 170–204, contains only the PDZ-BM of STK35L1) was localized to actin stress fibers. EGFP-STK35L1D1-169
mutant (lacking NoLS and NLS) was distributed throughout the nucleus and cytoplasm with a partial localization to fiber like structures of the
cytoskeleton. EGFP-STK35L1D1-96 (lacking NoLS, NLS and PDZ-BM) was diffusely distributed throughout the cytoplasm and the nucleus but no green
fiber like structures were visible.
doi:10.1371/journal.pone.0016249.g003
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terminal part of the protein. We found an interaction of STK35L1
with nuclear actin that is mediated through a potential PDZ-BM
motif present in the N-terminal part of STK35L1. Furthermore,
STK35L1 regulates the expression of CDKN2A and inhibits the
G1-to S-phase transition of the cell cycle, and STK35L1 is
essential for endothelial cell migration and cord-like structure
formation on Matrigel.
The N-terminal part of STK35L1 is highly basic and rich in
arginine and lysine and contains the bipartite NLS and NoLS. The
identified bipartite NLS sequence was conserved among mam-
mals, and we showed that it was functional in endothelial cells.
Our study further shows that the bipartite NLS (aa 142–153) did
not overlap with the NoLS sequences (aa 1–133) of STK35L1.
Nucleolar localizing proteins are rich in arginine and lysine and
often overlap with the NLS, suggesting a complex regulation of
nucleolar localization [29]. Other studies have identified small
NoLS sequence motifs ranging from 7 to 30 residues have been
identified that can be sufficient to target a protein to the nucleolus
[22,30]. We found that NoLS of STK35L1 had no well-defined
small sequence motif.
In terms of functions, we show that STK35L1 is a negative
regulator of the G1 to S phase progression of the endothelial cell
cycle by increasing directly or indirectly the expression of the cell
cycle inhibitor CDKN2A. Previously, high expression of
CDKN2A was correlated with a low proliferation of colorectal
carcinomas at the invasion front [31]. Moreover, enhanced levels
of STK35L1 transcripts have been reported in tissues obtained
from colorectal cancer patients [19]. Interestingly, by using
Phosphoproteomics of the Kinome across the Cell Cycle,
Figure 4. G1 to S-phase progression is accelerated in STK35L1-silenced endothelial cells. A) STK35L1 expression level of STK35L1 silenced
cells and control cells. B) Cell cycle distribution of control siRNA- and STK35L1 siRNA treated endothelial cells. Cells arrested in Go/G1 phase were
stimulated by serum for various times. Values are mean 6 S.E. of three independent experiments. Asterisk ‘‘*’’ indicates level of significance p#0. 05.
doi:10.1371/journal.pone.0016249.g004
STK35L1 Regulates Cell Cycle and Cell Migration
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16249STK35 (N-terminal 133 aa truncated-form of STK35L1) was
found to be phosphorylated during the cell cycle progression in
HeLa S3 cells. This study identified Thr-12 in STK35 as
phosphorylated amino acid, which corresponds to Thr-145 in
STK35L1 [32]. Notably, Thr-145 is within the bipartite NLS
sequence (STK35L1 aa 142–153) identified in the present study.
Many proteins such as LIMK2, Ca
2+/calmodulin-dependent
protein kinase II, and cyclin B1 are phosphorylated near or
within their NLS thereby affecting their nucleocytoplasmic
shuttling [22,33,34]. These results are interesting and lead us to
suggest that phosphorylation of STK35L1 within its NLS during
cell cycle progression might regulate its localization in the nucleus
and/or nucleolus.
Our study shows that STK35L1 is upstream of CDKN2A.
STK35L1 regulation of the CDNKN2A alpha-transcript
(p16
INK4a) could be a new signaling pathway regulating G1 to S
phase progression of the cell cycle. It has been shown that nuclear
b-catenin stimulates the expression of p16
INK4a in various tumor
cell lines but the mechanism of regulation is not well understood
[31,35]. Interestingly, GSK3b-dependent phosphorylation regu-
lates proteasomal degradation of b-catenin [36] and STK35 is a
potential candidate for GSK3b-regulated proteasomal degrada-
tion [37]. Therefore, there are now two possibilities for regulation
of CDKN2A (p16
INK4a): either a novel GSK3b/STK35L1
pathway regulates independently of GSK3b/b-catenin CDKN2A,
or STK35L1 is part of the GSK3b/b-catenin pathway regulating
CDKN2A. These possibilities should be explored further as
CDKN2A expression is important in various human diseases.
We found a crucial role of STK35L1 in endothelial cell
migration as measured by two different cell migration assays. The
question arises, how nuclear/nucleolar STK35L1 can regulate cell
migration? Previous studies showed that G1 to S phase progression
and cell migration are coordinated processes in different cell type:
cells in mid-late G1 phase have the greatest ability to migrate,
whereas cells in G0, S or G2/M phase have a lower or no ability to
move [14,15]. Therefore, it is possible that STK35L1 might
promote endothelial cell migration by keeping cells in the G1-
phase. Many cell cycle proteins have been reported to be involved
in the regulation of cell migration [11,13,38,39]. In endothelial
cells and vascular smooth muscle cells, the CDK inhibitor p27
Kip1
blocks cell migration [11,13], however in other studies p27
Kip1 has
been reported to promote migration by interacting with the G1/S-
phase specific cyclin D1 [38]. The subcellular distribution of
p27
Kip1 was found to be important in its promigratory function:
cytoplasmic but not nuclear p27
Kip1 promoted cellular migration
[39]. In our study, we could not find an altered subcellular
distribution of STK35L1 during endothelial cell migration
suggesting that the role of STK35L1 in regulating migration is
restricted to its nuclear/nucleolar localization.
Endothelial cell migration is required for angiogenesis. Endo-
thelial cells on Matrigel migrate, polarize and proceed to form
cord-like structures, but they do not proliferate [28]. Indeed we
found that STK35L1 is upregulated in endothelial cells growing
on Matrigel for 4 hours but not on collagen, and that STK35L1
was crucial for endothelial sprouting. We suggest that STK35L1
regulates this process by keeping endothelial cells in the G1 phase
and thereby promoting cell migration.
We identified nuclear actin as interacting protein of STK35L1.
The interaction of STK35L1 with nuclear actin might be
important for the regulation of both the cell cycle and the
migration of endothelial cells [40,41,42]. It is now well established
that actin is present in various nuclear compartments such as the
nucleolus. Nuclear actin forms structures different of cytosolic
actin structures such as stress fibers [41]. Nuclear actin plays a role
in gene transcription by regulation of transcription factors or as a
component of chromatin remodeling complexes and RNP
particles, and it is closely associated with all RNA polymerases
[42]. For example, nuclear actin regulates the Serum response
factor (SRF) by interacting with MAL, a Myocardin family
transcription factor. SRF activity is a key event during cellular
differentiation of many processes and transcriptionally controls
many genes such as actin isoforms (Actb, Actg, Acta2) and actin-
binding proteins (ABPs; e.g., Gsn) [43,44]. Recently, It has been
shows that SRF’s play a crucial function during cell migration. In
neuronal cells, cell migration is not only depends on cytoplasmic
actin dynamics but also on the nuclear actin dependent functions
such as gene transcription [45]. The nuclear actin/STK35L1
complex might regulate gene transcription of specific cell cycle
proteins such as CDKN2A and genes involved in cell migration.
[45]
Based on our results, it is not clear whether STK35L1
interacts directly or indirectly with actin. We identified a putative
Table 1. mRNA expression of selected cell cycle specific genes in STK35L1-silenced cells.
Reference Sequence Description Gene Symbol Fold Regulation p-value
NM_004701 Cyclin B2 CCNB2 23.605 0.060
NM_001786 Cell division cycle 2 CDC2 22.9966 0.030*
NM_001255 Cell division cycle 20 homolog (S. cerevisiae) CDC20 22.9282 0.055
NM_001259 Cyclin-dependent kinase 6 CDK6 22.7321 0.005*
NM_000077 Cyclin-dependent kinase inhibitor 2A (p16
INK4A) CDKN2A 28.8766 0.050*
NM_005192 Cyclin-dependent kinase inhibitor 3 CDKN3 23.4422 0.060
NM_004399 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 DDX11 24.7568 0.014*
NM_001924 Growth arrest and DNA-damage-inducible, alpha GADD45A 24.6482 0.030*
NM_016426 G-2 and S-phase expressed 1 GTSE1 22.9966 0.029*
NM_002417 Antigen identified by monoclonal antibody Ki-67 MKI67 22.7959 0.015*
NM_002875 RAD51 homolog RAD51 22.8613 0.022*
NM_003885 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) CDK5R1 2.09 0.078
Mean fold change of mRNA expression of selected cell cycle specific genes in STK35L1-silenced cells vs. control cells.
*Statistically significant (P value of #0.05).
doi:10.1371/journal.pone.0016249.t001
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STK35L1 that bound to actin. This suggests that STK35L1 may
be a ligand for a PDZ domain containing protein. Since actin
does not contain a PDZ domain, it is unlikely that STK35L1
through its PDZ domain-binding motif interacts directly with
actin. The interaction should then be mediated by PDZ domain
containing actin-binding proteins. Various PDZ containing
proteins such as PDZ-LIM family proteins (CLP36) are known
to interact with actin indirectly through binding to actin binding
proteins [25,46]. For example, the binding of CLP-36 to stress
fibers is mediated by its binding to actinin [24]. It is not known
whether nuclear actin also interacts with a PDZ domain
containing protein.
Together the present study unravels an important new player in
the orchestrated regulation of cell proliferation and migration of
endothelial cells. STK35L1 by inhibiting the endothelial cell cycle
and being essential for migration is important in regulating
vascular healing and angiogenesis. The interaction of STK35L1
with nuclear actin might be critical in the regulation of these
cellular processes.
Materials and Methods
Materials
Oligonucleotides and siRNAs were synthesized by MWG
Biotech AG (Ebersberg, Germany). Anti-b-actin was purchased
from Chemicon, Germany. Anti-p16
INK4A antibody was pur-
chased from Cell Signaling Technology and anti-b-tubulin
antibody from Abcam, Germany. FLAG-M2 gel slurry was
purchased from Sigma, Germany. Complete mini protease
inhibitors tablets were purchased from Roche Diagnostics,
Germany. Glutathione beads and GSTrap FF columns were
purchased from GE Healthcare, Lifesciences, Germany.
Construction of the Expression Plasmids and site-
directed mutagenesis
The full-length coding sequence of STK35L1 was cloned into
pEGFP-C1 vector as described previously [18]. The deletion
mutants of pEGFP-STK35L1 were generated by Quick-Change II
site-directed mutagenesis kit (Stratagene) as per manufacturer’s
instructions. To prepare GST-PDM construct, the PDZ binding
Figure 5. STK35L1 regulates endothelial morphogenesis. A) STK35L1 expression in endothelial cells cultivated in the presence of VEGF on
collagen or on Matrigel. The expression level of STK35L1 transcripts at the indicated time points was analyzed by RT-PCR. The relative expression level
compared to time 0 hr is shown. B) and C) STK35L1 regulates the formation of cord-like structures on Matrigel. Control siRNA and STK35L1-siRNA
transfected cells were grown on Matrigel for 6 h. B) phase contrast micrograph, Scale bar 500 mm. (C) Bar diagram, values are mean 6 S.E. of three
independent experiments; * p,0.05.
doi:10.1371/journal.pone.0016249.g005
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STK35L1 was amplified by PCR. The PCR-amplified product
was cloned into EcoRI and XhoI sites of into pGEX-5X-1 plasmid
(GE healthcare, Lifesciences) to obtain PDZ-BM containing
protein fragment fused with GST.
Cell Culture and Transfection
HUVECs (Human Umbilical Vein Endothelial cells) were
obtained and cultured as described previously [47]. Briefly,
endothelial cells (HUVECs) harvested from umbilical cords were
plated onto collagen-coated plastic culture flasks, and were
Figure 6. STK35L1 is required for endothelial cell migration. A) Migration assay using the IBIDI insert. Endothelial cells transfected with
STK35L1 siRNA (red shaded part) or control siRNA (green shaded part) were seeded into different reservoirs of an IBIDI insert. After 8 hours the insert
was removed and the closure of the gap was observed by video microscopy. The pictures from one experiment representative of three are shown,
Scale bar 100 mm. B) Migration after mechanical injury. Left panel, representative micrographs, cells treated with control siRNA, or cells treated with
STK35L1 siRNA are shown immediately 0 hr or 7 hr after mechanical injury; width of the wound is shown in mm. Right panel, Bar diagram, wound
closure was quantified as described in the method section. Values are mean 6 S.E. of three independent experiments; ‘*’, p,0.05.
doi:10.1371/journal.pone.0016249.g006
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medium (endothelial cell basal medium with supplements; Promo
Cell, Germany). In all experiments, HUVECs were transfected
with 5 mg DNA per 1610
6 cells using the HUVEC nucleofactor
kit from Amaxa GmbH.
Isolation of cell nuclei
Nuclei of EGFP-FLAG-STK35 or EGFP-FLAG-transfected or
non-transfected endothelial and HEK 293T [18] and HeLa cells
(DSMZ - Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH) were isolated using nuclei Isolation Kit:
Nuclei EZ prep (Sigma) as per manufacturer’s instructions. Briefly,
the cells grown in tissue culture Ø 10 cm dish, washed with ice
cold PBS twice and then 4 ml of ice cold Nuclei EZ lysis buffer was
added to each dish. The cells were harvested and lysed by
thoroughly scraping and then transferred to a 15 ml centrifuge
tube, The nuclei were collected by centrifugation at 5006g for 5
minutes at 4uC and the nuclei pellet was washed by resuspending
in cold Nuclei EZ lysis buffer. The washed nuclei were collected by
centrifugation at 5006g for 5 minutes at 4uC and use for
immunoprecipitation or GST pull down assay.
Immunoprecipitation of EGFP-FLAG-STK35 from nuclear
lysates
Immunoprecipitationfrom nuclearlysate wasperformed using the
Nuclear CO-IP-Kit (Active motif) according to the manufacturers’
recommendations. In brief, the nuclei, EGFP-FLAG-STK35-
transfected cells were resuspended in 50 ml complete digestion buffer
(CDB). Enzymatic shearing cocktail (0.25 ml) was added in the nuclei
suspension, incubated for 90 minutes at 4uC. Subsequently, the
reaction was stopped by addition of 1 ml EDTA (0.5 M). After gentle
vortexing the tube was incubated 5 minutes on ice. The nuclear
debris was removed by centrifugation for 10 minutes at 14,0006g
4uC. The supernatant, containing nuclear proteins, was diluted in
500 ml IP-incubation buffer, and 30 ml of anti-FLAG-M2 gel-slurry
(Sigma; 36 washed with 5 volumes of IP-incubation buffer) was
added to the solution and incubated overnight at 4uC. The next day,
the suspension was centrifuged 30 sec 40006ga t4 uC The beads
were washed 6 times with IP-wash buffer and finally resuspended in
60 ml1 6 Laemmli-buffer and boiled for 5 minutes at 95uCa n d
subjected to SDS-PAGE and western blotting.
Western blotting
Western blotting was done as described previously [47] using as
primary antibodies anti-b-actin (1:100 000), anti-p16
INK4A (dilution
1:500 to 1:200) and anti-b-tubulin antibody (1:500 dilution).
Mass spectroscopy
The coimmunoprecipitated and coomassie-stained protein
bands were excised from the SDS-PAGE gel and sent to the
Zentrallabor fu ¨r Proteinanalytik (Ludwig-Maximilians-Universita ¨t
Munich, Germany) for protein identification by MALDI TOF-MS
analysis. There, the proteins were in gel digested to peptides by the
endoproteinase trypsin. Peptides were eluted and directly spotted
on a MALDI sample plate. MALDI-TOF measurements were
performed, and the resulting spectra were then analyzed via
Mascot software (Matrix Science, London, United Kingdom)
using the NCBI Protein Databank.
Expression and purification of recombinant GST and GST-
PDM
GST and GST-PDM plasmids were overexpressed in BL21
(DE3) pLysS (Stratagene) at 37uC after the addition of 0.5 mM
isopropyl b-d-thiogalactoside at an A600 of ,0.6 for three hours.
Bacteria were harvested by centrifugation and resuspended in
10 ml of ice cold PBS buffer containing lysozyme (1 mg/ml) and
complete mini protease inhibitors (Roche Diagnostics) and
incubated on ice for 30 minutes. The bacterial cells were lysed
by sonication and then Triton X-100 (1%) was added. Cell debris
was removed by centrifugation at 600006g and the supernatant
was loaded on GSTrap FF column (GE Healthcare, lifesciences)
pre-equibilirated with PBS. The column was then washed with
PBS and bound GST-tagged protein was eluted with elution buffer
(50 mM Tris base, 10 mM Glutathione; pH 8.0). The eluted
fractions were pooled, and concentrated and desalted using
CentriconH Plus-20 (Millipore).
GST pull down assay
The nuclei from three culture flasks (75 cm
2) of confluent
endothelial cells were isolated, and nuclear protein extracts were
prepared as described above. Nuclear protein extract (1 ml) was
aliquoted equally in two microcentrifuge tubes. Purified GST or
GST-PDM protein was added to each tube and incubated
overnight at 4uC. Glutathione-Sepharose beads (GE-healthcare,
Lifesciences; 50 ml; 3 times washed with 5 volumes of IP-
incubation buffer) were added and samples were incubated for
one hour at 4uC. The beads were pelleted by centrifugation,
washed 6 times with IP-wash buffer and finally resuspended in
60 ml1 6 Laemmli-buffer and boiled for 5 minutes at 95uC and
subjected to SDS-PAGE and western blotting.
Immunofluorescent staining and fluorescence
microscopy
After 8–10 hours of transfection, cells were washed and fixed
with 3.7% formaldehyde in PBS for 10 minutes at 4uC and then
washed briefly 2 times with PBS. For permeabilization, the cells
were incubated in 0.2% TritonX100/PBS for 10 minutes at room
temperature followed by 3 times washing with PBS. For immuno-
staining of nuclear actin, the fixed and permeabilized cells were
incubated with blocking solution (2% fatty acid free BSA in PBS)
for 30 minutes at room temperature, briefly rinsed with PBS and
then incubated with anti-actin monoclonal antibody (clone 4,
1:100 dilution) for one hour in humidified chamber. Cells were
washed three times with PBS and incubated with Alexa FluorH568
goat anti-mouse secondary antibody (1:200 dilution) for 45
minutes at room temperature and then washed 3 times. For
DNA staining, cells were incubated with Hoechst 33258 dye
(1 mg/ml) for 10 minutes. Cells were observed with a Nikon
TE2000E-PFS fluorescence microscope.
STK35L1-silencing
STK35L1 specific siRNAs were designed directed against three
different regions of STK35L1 gene[18]. For silencing, HUVECs
were grown to 90% confluence in 6-well plates in complete
endothelial cell growth medium. Before 24 hours of transfection,
the cell growth medium was changed to OptiMEM medium
containing 0.5% FCS without antibiotics. HUVEC were trans-
fected with a pool of three siRNA using Oligofectamine
TM
(Invitrogen, Germany) for 48 hours according to manufacturer’s
protocol.
Endothelial cell viability and cell proliferation assay
To measure endothelial cell viability, cells were centrifuged, and
resuspended in PBS buffer after trypsinization. Cells were mixed
with trypan blue (0.4%; Sigma) in a 1:1 ratio and were incubated
for 3minutes at room temperature. Cell viability was calculated by
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hemocytometer.
For endothelial cell proliferation assay, cells were grown in 24
well plates in complete endothelial growth medium. AlamarBlueH
(Invitrogen) [48] reagent was added (1/10
th of volume of growth
medium in each well) at different time points (24 hrs, 48 hours and
72 hours) and incubated for 4 hours at 37uC. The absorbance was
measured at 570 nm and at 690 nm as reference wavelength
(normalized to the 690 nm value) using Mithras LB 940
Multimode Reader. Cell proliferation is directly correlated to the
absorbance value of developed color. The absorbance of control
siRNA treated cells was considered as 100% and the proliferation
was calculated as % of control (Figure S2).
RT-PCR
To measure the STK35L1 expression in silenced-cells, or in
other experiments, the cells, grown on collagen or on Matrigel
were harvested by trypsinization or by using BD
TM cell recovery
solution, respectively. Total RNA was isolated from the harvested
cells using RNeasy mini kit (Qiagen, Germany). First-strand
cDNAs were synthesized with Omniscript reverse transcriptase kit
(Qiagen) using random hexamer primers as per manufacturer’s
protocol. The relative expression of a STK35L1 transcript was
measured by quantitative RT_PCR using PuReTaq Ready-To Go
qPCR beads (GE Lifesciences) as per manufacturer’s instructions.
The data was normalized against the b-actin gene.
Cell cycle analysis of endothelial cells
Endothelial cells, transfected with STK35L1 siRNA or control
siRNA, were grown to confluence. Twenty-four hours after
transfection, the cells were trypsinized, split in a 1:2 ratio, replated
and cultivated in serum-free medium for 24 hours. The cells were
then released into the normal cell cycle progression by changing
the medium to endothelial growth medium containing 10% FCS.
The cells were harvested 6, 12, and 24 hours after release from
starvation. Cells were fixed by adding 90% methanol drop-wise to
the cell pellet. The cell suspension was kept for 30 minutes at 4uC
and then cells were pelleted at 800 rpm followed by two times
washing with PBS. Finally the cell pellet was resuspended in
Propidium iodide, incubated at 37u for 1 hour and then analyzed
by FACS (FACSCalibur flow cytometer, Becton Dickinson). The
cell cycle data were analyzed by Modefit software.
Cell-cycle RT
2 Profiler
TM PCR Array
Endothelial cells, transfected with STK35L1 siRNA or control
siRNA were grown to confluence for 24 hours. The cells were
trypsinized, splitted in a 1:2 ratio, re-seeded and grown in
endothelial cell basal medium (Promo cell) containing 0.5% serum
for 24 hours. The cells were then released into normal cell cycle
progression by changing the medium to complete endothelial cell
growth medium containing 10% FCS. The cells were harvested six
hours after release from starvation and total RNA was isolated by
using the RNeasy mini kit (Qiagen). The RNA was reverse
transcribed using the specific RT
2 First Strand Kit (SA
Biosciences). cDNA (2 mg) of STK35L1-silenced and control cells
were mixed with RT
2 qPCR Master Mix. The mixture was
aliquoted into each well of the 96 well PCR array plate containing
pre-dispensed gene specific primer sets. Quantitative real time
PCR of 96 well plate was performed by using the iCycler (BioRad).
Baseline and threshold values of real-time PCR were defined
manually and were kept the same across the PCR array. The
resulting threshold cycle values for all wells were exported to
Microsoft Excel for use with the Data Analysis Template Excel
file. For the analysis of these RT-PCR data, we used 4 control
genes to calculate the normalization factor: b-2-microglobulin
(B2M), hypoxanthine phosphoribosyl-transferase 1 (HPRT1),
ribosomal protein L13a (RPL13A), and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH). Data were generated from three
independent silencing experiments (n=3). We considered the
genes, whose expression was significantly up- or down-regulated
by a factor of .4 (P value of #0.05).
Matrigel cord formation assay
MatrigelH (BD Biosciences) was thawed on ice overnight, and
10 ml were pipetted with ice cold pipette tips into the lower
chambers of an IBIDI angiogenesis slide (IBIDI GmbH,) and
allowed to harden for 30 minutes at 37uC. After 48 hours of
siRNA transfection, STK35L1-silenced and control cells were
trypsinized and resuspended in complete endothelial growth
medium. Transfected cells were more than 95% viable. The cell
suspension (50 ml; 3610
5 cells/ml) was seeded on Matrigel into the
well. The cells were incubated at 37uC and cord formation was
observed on Nikon TE2000E-PFS fluorescence microscope. After
six hours of seeding, pictures were taken and the images were
analyzed with NIS Elements software. Network formation was
quantified by measuring the total cord length and compared
between silenced and non-silenced cells.
Endothelial cell Migration after mechanical injury
HUVECs were seeded onto collagen coated six-well plate and
following 24 hours of starvation the cell layer was scratched once
from one edge to the other edge of the well using a pipette tip. The
cells were washed with endothelial growth medium to remove cell
debris and then incubated in complete endothelial growth
medium. Wound healing was determined by measuring the cell-
free area reaming in the wound, which is inversely correlates with
the ability of the HUVECs to migrate.
Endothelial cell migration using the IBIDI culture insert
An IBIDI culture insert (IBIDI GmbH) consists of two reservoirs
separated by a 500 mm thick wall. For the endothelial migration
assay, a BIDI culture insert was placed into one well of the 24 well
plate and slightly pressed on the top to ensure tight adhesion. An
equal number of control and STK35L1-silenced endothelial cell
(70 ml; 4610
5 cells/ml) were added into the two reservoirs of the
same insert and incubated at 37uC/5% CO2. After 10 hours, the
insert was gently removed creating a gap of ,500 mm. The well
was filled with complete endothelial growth and the migration was
observed by live cell imaging using Nikon TE2000E-PFS
microscope.
Supporting Information
Figure S1 Protein sequence alignment of mammalian
STK35L1. N-terminal region and kinase domain of STK35L1
are shaded in gray and yellow color respectively. The conserved
bipartite NLS (boxed) is marked in red color. Stretches of arginine
and lysine are colored in gold.
(PDF)
Figure S2 Endothelial cell prolifiration using Alamar-
BlueH. HUVECs were seeded (25000 cells/well) in 24 well plates
and were grown for 24 hours, 48 hours and 72 hours. Before four
hours of every time points, cells were incubated with AlamarBlue
reagent as described in Materials and methods. The absorbance of
control siRNA treated cells was considered as 100% and the
proliferation was calculated as % of control.
(JPG)
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STK35L1 using the ELM web server. Predicted binding
motifs within STK35L1 are shown. The consensus binding
sequence for the given binding domains is labeled in red. LIG,
binding for.
(PDF)
Table S2 List of genes and their position on the RT-PCR
array 96 well plate.
(PDF)
Movie S1 Live cell imaging of human endothelial cells
transfected with EGFP-PDM. EGFP-PDM containing the
PDZ-binding motif (see text for details), distributes thought the
cytoplasm and the nucleus. In migrating cells, it concentrates in
membrane ruffles at the leading edge as indicated by white arrows.
Pictures were taken every four minutes for 90 minutes. Movie was
edited with QuickTime Pro and iMovie software from Apple Inc.
(MOV)
Movie S2 Migration assay using the IBIDI insert.
Endothelial cells transfected with STK35L1 siRNA (left side) or
control siRNA (right side) were seeded into different reservoirs of
an IBIDI insert. After 8 hours the insert was removed and the
closure of the gap was observed on Nikon TE2000E-PFS
fluorescence microscope equipped with incubation camber
(37uC) and CO2 supply. The microscope function was controlled
by NIS elements software. Pictures were taken every 7 minutes for
15 hours. Movie was edited with QuickTime Pro and iMovie
software from Apple Inc.
(MOV)
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